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Abstract
Background: The surgical treatment of patients with advanced-stage ovarian cancer is based on maximal
cytoreduction with widening the debulking on the extra-ovarian tissues and infiltrated organs. The purpose of the
study was to assess the outcome after optimal cytoreduction with partial bowel resection and to find the risk
factors of relapse. Another goal was the quantitative and qualitative assessment of intra- and postoperative
complications in the studied group.
Methods: The analysis of debulking procedures with intestinal resection and postoperative period in 33 ovarian
cancer patients, The International Federation of Gynecology and Obstetrics (FIGO) stages III and IV, was performed.
Results: The optimal cytoreduction defined as less than 1.0 cm residual disease was achieved in all patients including
the following: 26 patients (78.8 %) with no macroscopic residual disease, 4 patients (12.1 %) with the largest residual
tumor less than 0.5, and 3 patients (9.1 %) with 0.5 cm to less than 1.0 cm residual disease. The rectosigmoid resection
was the most common surgical procedure (n = 27). The risk of relapse was significantly higher in subjects who had the
macroscopic residual tumor left during the primary operation (57.1 vs. 11.5 %, P = 0.035). A primary bowel tumor size
was another predictor of relapse. The maximum tumor diameter was significantly larger (14.9 ± 6.7 cm vs. 10.3 ± 4.7 cm,
P = 0.047) in patients who developed the relapse.
Conclusions: As presented in the article, our outcomes and other authors’ observations indicate that debulking
surgery with bowel resection in patients with advanced ovarian cancer brings good results. Complications connected
with bowel surgery are to be accepted. The interesting thing is that a primary bowel tumor size was a predictor of
relapse.
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Background
Ovarian cancer incidence has been on a steady rise in
recent years. In 2011 alone, 3257 new cases of ovarian
cancer were diagnosed in Poland, of which 70 % were
The International Federation of Gynecology and Obstet-
rics (FIGO) stage III and IV cancers. In the same year,
2558 ovarian cancer-related deaths were recorded [1]. In
European women, ovarian cancer constitutes 4 % of
cancers and is the sixth most common cause of cancer-
related death [2].
The treatment of patients with advanced-stage ovarian
cancer is based on surgery and adjuvant chemotherapy.
The surgeon aims into achieving a maximal possible
cytoreduction, while at the same time minimizing the
trauma to the patient. The goal of surgery is optimal
surgical cytoreduction, which is defined as residual dis-
ease of 10 mm or less [3]. Numerous studies have shown
that the prognosis improves with the reduction of tumor
volume at the end of surgery and that the patients in
whom the removal of all grossly evident tumor (i.e.,
“complete” cytoreduction) was possible have the best
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prognosis [4–6]. In recent years, a trend to improve
cytoreduction by performing surgery on the extra-
ovarian tissues and organs infiltrated by the tumor has
become apparent. A few series of extended surgical pro-
cedures including abdominal and diaphragmatic perito-
nectomy, partial liver resection, and partial
pancreatectomy or splenectomy have been published.
The resections of parts of the digestive tract, especially
the large bowel, are increasingly commonly performed
[7–9]. According to the authors of those reports, the risk
associated with such procedures seems justified in view
of an improved prognosis.
Even though this type of surgery is usually performed
in expert gynecologic oncology centers, it seems to be
associated with a higher rate of intraoperative and early
postoperative complications such as bleeding, anasto-
motic dehiscence, and infection. In selected patients, os-
tomy becomes necessary, which inevitably leads to a
significant deterioration of the comfort of living. At this
point, it becomes debatable whether the advantages of
optimal cytoreduction during primary treatment are suf-
ficient to compensate for the risks of extended surgery.
The purpose of the study was to assess the outcome
after optimal cytoreduction with partial bowel resection
and to find the risk factors of relapse. Another goal was
the quantitative and qualitative assessment of intra- and
postoperative complications in the studied group.
Methods
Between October 2010 and December 2013, 33 extended
first-line surgeries with partial bowel resection were per-
formed in patients with FIGO stage III and IV ovarian
cancer. Multi-detector computed tomography (MDCT)
or magnetic resonance imaging (MRI) with diffusion-
weighted imaging were performed in all subjects during
qualification for optimal cytoreduction to assess the ex-
tent of the tumor spread and likelihood of the necessity
to perform a bowel resection. The exclusion criteria for
primary surgery included tumor deposits covering a
greater part of the parietal peritoneum and enteric sur-
face, combined infiltration of the periaortic space and
mesentery, and infiltration of the hepatic hilum. Patients
meeting the exclusion criteria were referred for neoadiu-
vant chemotherapy (PCL + CBDCA) provided the diag-
nosis of cancer was confirmed by laparoscopic biopsy or
the presence of the neoplastic cells in the peritoneal
fluid taken during paracentesis. In the second situation,
the CA125/CEA ratio was required to be more than 25.
After three courses of chemotherapy, the patients under-
went MDCT and were requalified to cytoreduction sur-
gery. The presence of up to several limited peritoneal
implants was not considered a contraindication to sur-
gery. In equivocal cases, diagnostic laparoscopy was pre-
formed shortly before planned surgery. One day before
the surgery, the patients underwent bowel preparation
with cathartics and cleansing enemas. Antibiotic and an-
tithrombotic prophylaxis was administered in all pa-
tients. The final decision about performing bowel
resection and about its extent was undertaken during
the surgery.
In the descriptive analysis of the results, the following
parameters were taken into account: a maximum diam-
eter of the resected tumor, type of surgical procedure,
perioperative blood loss, need for reoperation, postoper-
ative complications including wound infection and fever
>38 °C for longer than 48 h, hospital stay length, and
time from surgery to the onset of chemotherapy.
The response to treatment and time to progression
were used as clinical endpoints for this study. The pa-
tients with the relapse were compared with the subjects
who had no relapse during the observation. The detailed
characteristics of the patients are presented in Table 1.
Results
The optimal cytoreduction defined as less than 1.0 cm
residual disease was achieved in all patients including
the following: 26 patients (78.7 %) with no macroscopic
residual disease, 4 patients (12.1 %) with the largest re-
sidual tumor less than 0.5, and 3 patients (9.1 %) with
0.5 cm to less than 1.0 cm residual disease.
The rectosigmoid resection was the most common
surgical procedure (n = 27). The right hemicolectomy
was performed in two patients, and the left hemicolect-
omy was also performed in three patients. In one case,
the right hemicolectomy was accompanied by the recto-
sigmoid resection.
In 32 cases, the colon was reanastomosed using the
end-to-end or side-to-side anastomosis stapler. One pa-
tient had two stapler anastomoses and required a pro-
tective colostomy. In one case, the presence of
obstruction was the reason for a colostomy. The details
of surgical procedures are shown in Table 2.
The postoperative period was uneventful in most pa-
tients. Neither fever nor deep vein thrombosis was ob-
served in any case after the operation. One patient
required reoperation due to gastric ulcer perforation.
Abnormal wound healing was observed in three patients,
but only one case required resuturing (Table 3).
The median follow-up time was 656.9 ± 332.2 days
(175–1312 days). The relapse was observed in seven pa-
tients (21.2 %). Five of them presented intraperitoneal
spread. Local relapse in the pelvis was diagnosed in two
cases. The mean progression-free survival (PFS) time
was 411.0 ± 209.9 days. Four patients with the relapse
died. The mean overall survival was 775.8 ± 521.4 days
in this group. The detailed outcome is presented in
Table 4. No deaths were observed in the group without
the relapse during observation.
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In the whole group of optimal operated patients
(residual disease <1.0 cm), the risk of relapse was sig-
nificantly higher in subjects who had the macroscopic
residual tumor left during the primary operation (57.1
vs. 11.5 %, P = 0.035). The size of primary ovarian
tumor that infiltrated the bowel was another predictor
of relapse. The maximum tumor diameter was signifi-
cantly larger (14.9 ± 6.7 vs. 10.3 ± 4.7 cm, P = 0.047) in
patients who developed the relapse. There was no as-
sociation between the incidence of relapse and the
initial CA 125 level or time from the operation to the
onset of chemotherapy. Serum Ca125 level, patient’s
age, the duration of operation, and perioperative
blood loss did not differ in subjects with no and
minimal (less than 1.0 cm) residual disease after the
primary surgery (Table 5).
Discussion
Cytoreductive surgeries performed in patients with
advanced-stage ovarian cancer are among the most chal-
lenging in gynecologic oncology. Since the publication
by Griffiths showing that survival is improved if the
diameter of residual tumor implants after debulking does
not exceed 15 mm, achieving the optimal cytoreduction
became the main goal of surgery [10]. At present, the
bulk of residual tumor is considered a main prognostic
factor in patients treated with adjuvant chemotherapy
with platinum (till the last decade of the twentieth cen-
tury) and, more recently, with platinum and paclitaxel
[11]. With time, the mass of residual tumor that still al-
lows for calling surgery “radical” or “optimal” has been
reduced, and at present, surgery is called “optimal” when
no macroscopic tumor foci are left [4, 5, 12]. If possible,
no tumor implants larger than 10 mm should be present
at the end of surgery [13]. This strategy sometimes re-
quires multiorgan resections. Most commonly, the parts
Table 1 Patient characteristics
All patientsN = 33 No relapse groupN = 26 Relapse groupN = 7 P
Age (years ± SD) 58 ± 10.4 56.7 ± 9.7 62.9 ± 13.1 NS
FIGO NS
II 1 (3 %) 1 (3.8 %) 0 (0 %)
III 31 (94 %) 24 (92.4 %) 7 (100 %)
IV 1 (3 %) 1 (3.8 %) 0 (0 %)
Histopathology NS
Serous 20 (60.7 %) 15 (57.7 %) 5 (71.4 %)
Endometrioid 8 (24.2 %) 8 (30.8 %) 0 (0 %)
Mucinous 1 (3 %) 1 (3.8 %) 0 (0 %)
Clear cell 4 (12.1 %) 2 (7.7 %) 2 (29.6 %)
Grading NS
G1 1 (3 %) 1 (3.8 %) 0 (0 %)
G2 15 (45.5 %) 13 (50 %) 2 (29.6 %)
G3 17 (51.5 %) 12 (44.2 %) 5 (71.4 %)
Table 2 Surgical procedures in patients with ovarian cancer
Surgical technique Number
Sigmoid or rectosigmoid resection 28 (84.8 %)a
Right hemicolectomy 3 (9.1 %)a
Left hemicolectomy 3 (9.1 %)
Stapler anastomosis 32(97 %)a
Colostomy 2 (6.1 %)a
Maximum tumor diameter (cm) 11.3 (±5.4)b
Optimal debulking <1.0 cm (n) 34 (100 %)
No macroscopic residual tumor 26 (78.8 %)
Residual tumor <0.5 cm 4 (12.1 %)
Residual tumor 0.5–<1.0 cm 3 (9.1 %)
Time of operation (min) 209.4 (±35.0)b
Time of hospitalization (days) 9 (±4.5)b
Intraoperative blood loss (ml) 964.7 (±566.8)b
aOne case subjected to a multiple procedure
bValues are mean ± SD
Table 3 Perioperative complications
Complication Number (%)
Heavy intraoperative bleeding (>1000 mL) 5 (15.5 %)
Fever 0 (0 %)
Abnormal wound healing 3 (9.1 %)
Anastomosis leak 0 (0 %)
Deep vein thrombosis 0 (0 %)
Gastric ulcer perforation 1 (3 %)
Prolonged hospitalization (>10 days) 5 (15.2%)
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of the digestive tract are resected, especially the large
bowel. The reports on such procedures from the begin-
ning of the twenty-first century showed promising re-
sults. In 2003, Bristow and coworkers published the
results of surgery in 31 patients with stage IIIb and IV
disease in whom rectosigmoid resection with stapler
anastomosis was performed [14]. The radical cytoreduc-
tion defined as no tumor residues larger than 10 mm
was achieved in 87.1 % of patients. There was no peri-
operative mortality, and an average blood loss was
700 ml. Anastomotic dehiscence occurred in one patient.
The overall rate of large (dehiscence, bleeding) and small
(fever, wound infection, pneumonia) complications was
12.9 and 35.5 %, respectively. Obermair and coworkers
reported 65 cytoreductive surgeries with rectosigmoid
resection and end-to-end anastomosis [15]. The optimal
cytoreduction was achieved in 48 patients. The compli-
cations included the following: one bowel fistula (1.5 %),
two cases of anastomotic dehiscence (3.1 %), two cases
of ileus (3.1 %), 14 cases of wound infection (21.5 %),
and five thromboembolic complications (7.7 %). Three
patients were reoperated [15]. One patient died immedi-
ately after the surgery. Chia et al. reported on the results
of surgery in 38 patients with advanced-stage ovarian
cancer [16]. The most often performed operative pro-
cedure in this group of patients was resection of the
sigmoid and rectum (76.3 %). Colostomy was performed
in 61 % of patients. Optimal cytoreduction was achieved
in 71 % of patients. Perioperative complications included
one anastomotic dehiscence (2.6 %), one enteric fistula
(2.6 %), and two interloop abscesses (5.3 %). Reoperation
was required in three patients. During 30 days after the
surgery, three patients died [16]. All aforementioned au-
thors were unanimous that cytoreduction with bowel re-
section, most often of the sigmoid and rectum, gives
good results and the rate of perioperative complications
is acceptable. However, in the last mentioned paper, a
high rate of colostomies brings attention. In 2007, we re-
ported our initial experience in performing rectosigmoid
resection or colectomy in patients with FIGO stage III
and IV ovarian cancer [9]. Our series from 2007 con-
sisted of 39 patients treated in a single center. We were
able to achieve a radical cytoreduction (macroscopic im-
plants <10 mm) in 32 patients (82 %). There were three
(7.6 %) cases of anastomotic dehiscence, and one patient
developed intestinal obstruction (2.5 %). The average
blood loss was 1120 ml, and the average surgery time
was 175 min. There were no perioperative deaths. Colos-
tomy was performed in 36.4 % of 39 patients. This rela-
tively high rate in early series of patients may be
expected to be reduced with growing increased experi-
ence. In comparison with this paper, a significant
Table 4 Characteristics of patients with relapse
Patient number Type of relapse PFS (days) Death OS (days) Follow-up (days)
1 Spread 334 Yes 523 523
2 Spread 252 Yes 675 675
3 Spread 236 Yes 375 375
4 Local 462 Yes 1538 1538
5 Local 854 No 1009
6 Spread 356 No 883
7 Spread 383 No 463
Mean 411.0 775.8 780.9
SD 209.9 521.4 404.0
Table 5 Perioperative outcomes
No relapse group (N = 26) Relapse group (N = 7) P
Maximum tumor diameter (cm) 14.9 ± 6.7 10.3 ± 4.7 0.047
Initial CA 125 (U/l) 642.7 ± 763.8 801.6 ± 1510.0 NS
Time from the operation to the onset of chemotherapy (days) 20.7 ± 5.2 19.7 ± 4.5 NS
No macroscopic residual tumor after operation 23 (88.5 %) 3 (42.9 %) 0.023
No residual disease group (N = 27) Minimal residual disease group (N = 7) P
Initial CA 125 (U/l) 548.4 ± 713.0 1088.7 ± 1425.4 NS
Duration of operation (min) 206.9 ± 32.0 229.3 ± 35.2 NS
Perioperative blood loss (ml) 900.0 ± 494.1 1242.9 ± 793.4 NS
Values are mean ± SD
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reduction can be stated in the percentage of ostomy with
increasing team experience.
In 2012, Peiretti and coworkers published the results
of the multicenter study which was conducted between
1998 and 2008 and included 238 patients with carcin-
oma of the ovary, fallopian tube, and peritoneum in
whom rectosigmoid resection was performed as a part
of cytoreductive surgery [17]. Stapler anastomosis was
performed in 98 % of patients. Ileostomy was performed
in two (0.8 %) and colostomy in five (2 %) of the pa-
tients. Complete cytoreduction was achieved in 41 % of
the patients. Anastomotic dehiscence occurred in nine
patients (3 %) [17].
Anastomotic dehiscence (AD) is one of most serious
complications related to bowel surgery, especially in rec-
tosigmoid resection with low anastomosis. The incidence
of this complication is between 2.8 and 23 % for resec-
tions of colonic cancer and between 0.8 and 6.8 % for
gynecologic cancers [14, 15, 18, 19]. A lower rate of
complications after gynecologic surgeries may be due to
less common performance of the so-called low resec-
tions. The mortality of AD ranges from 7.3 to 16 %, and
approximately one third of deaths related to colorectal
surgery is due to AD [20, 21]. The factors contributing
to a higher risk of AD include protracted surgery (sur-
gery time longer than 2 h), blood transfusion, and short
distal segment of anastomosis. It was suggested that re-
lieving ileo- or colostomy may be used as a protective
measure against this complication. On the other hand,
overall rate of complications associated with en-block
resection of the uterus and adnexa with tumor-
infiltrated rectosigmoid without protective ileostomy is
low, around 2 % [22]. Therefore, ileostomy should not
be performed on a routine basis but only in specific situ-
ations such as a lack of bowel preparation or presence of
factors worsening the prognosis, for instance, the neces-
sity to perform more than one anastomosis [23]. Simi-
larly, Hartmann’s procedure should be reserved only for
patients with significant comorbidities or as “salvage
procedure” [24].
Thorough preoperative work-out is a prerequisite of
optimal cytoreduction. Well-selected imaging studies
may help to avoid unnecessary surgery in patients with
large unresectable foci of tumor. MDCT has established
itself as an excellent tool for preoperative assessment of
patients with ovarian cancer. The recent papers confirm
high agreement of MDCT with both intraoperative and
pathologic assessment of resectability and clinical grad-
ing of ovarian cancer [25]. Magnetic resonance imaging
with diffusion-weighted imaging is very efficient in dem-
onstrating the infiltration of adjacent organs and small
peritoneal implants [26, 27]. High percentage of
complete and optimal cytoreduction in our group con-
firmed the usefulness of MDCT or MRI with diffusion-
weighted imaging during qualification for debulking
surgery.
Several papers have addressed the issue of influence of
extended surgery on survival. One of the first papers
was published by Scarabelli and coworkers [28]. Two-
year survival reached 100 % for patients without macro-
scopic tumor after surgery and 77 % for patients with
foci of 1 cm in diameter. None of the patients with re-
sidual disease larger than 2 cm had survived 2 years
[28]. According to the results of Takahashi and co-
workers, the 5-year cumulative survival rate was 60.8 %
in patients without residual disease and 0 % in patients
with macroscopic disease <1 and >1 cm [29]. What is in-
teresting about this report is also the observation that
cumulative 5-year survival in patients undergoing pri-
mary radical cytoreductive surgery with bowel resection
was 62.2 %, while that in patients operated after neoa-
diuvant chemotherapy was only 13.9 % [29]. Later retro-
spective studies also show promising results. Arora
analyzed a group of 203 women with FIGO stage IIIc
and IV ovarian cancer operated during a 10-year period
[30]. In 51 patients from this group, optimal cytoreduc-
tion was achieved with bowel resection. The median
follow-up time was 84 months (28–159). Two-year
disease-free survival was reached by 63 % of patients.
Considering that those results pertain to the patients
with the most advanced-stage ovarian cancer, they must
be perceived as satisfying. In an aforementioned paper
by Priretti and coworkers, the recurrence occurred in
50 % of 238 patients during the study period [17]. How-
ever, only 5 % of them showed a relapse at the level of
the pelvis whereas 8 % presented with abdominal recur-
rence associated with pelvic disease as well. The median
overall survival time among patients with complete
cytoreduction was 72 months compared with 42 months
among the rest of the patients (P = 0.002) [17].
Conclusions
As presented in the article, our outcomes and other
authors’ observations indicate that debulking surgery
with bowel resection in patients with advanced ovar-
ian cancer brings good results. Complications con-
nected with bowel surgery are to be accepted. The
interesting thing is that a primary bowel tumor size
was a predictor of relapse.
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